Abbvie Inc
NYSE:ABBV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Abbvie Inc
NYSE:ABBV
|
US |
|
Ashmore Group PLC
LSE:ASHM
|
UK |
|
Sonoro Gold Corp
XTSX:SGO
|
CA |
|
Axalta Coating Systems Ltd
NYSE:AXTA
|
US |
|
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
|
CN |
|
H
|
Horizon Robotics
HKEX:9660
|
CN |
|
Gr Sarantis SA
OTC:SRTSF
|
GR |
|
Nerdwallet Inc
NASDAQ:NRDS
|
US |
|
Oruka Therapeutics Inc
NASDAQ:ORKA
|
US |
|
Proximus NV
XBRU:PROX
|
BE |
Wall Street
Price Targets
ABBV Price Targets Summary
Abbvie Inc
According to Wall Street analysts, the average 1-year price target for
ABBV
is 256.47 USD
with a low forecast of 189.76 USD and a high forecast of 344.4 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ABBV's stock price target?
Price Target
256.47
USD
According to Wall Street analysts, the average 1-year price target for
ABBV
is 256.47 USD
with a low forecast of 189.76 USD and a high forecast of 344.4 USD.
What is Abbvie Inc's Revenue forecast?
Projected CAGR
9%
For the last 14 years the
compound annual growth rate for
Abbvie Inc's revenue is
9%.
The projected
CAGR
for the next 3 years is
9%.
What is Abbvie Inc's Operating Income forecast?
Projected CAGR
23%
For the last 14 years the
compound annual growth rate for
Abbvie Inc's operating income is
12%.
The projected
CAGR
for the next 3 years is
23%.
What is Abbvie Inc's Net Income forecast?
Projected CAGR
97%
For the last 14 years the
compound annual growth rate for
Abbvie Inc's net income is
1%.
The projected
CAGR
for the next 3 years is
97%.
